Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
March 10, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
March 04, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
February 02, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
January 05, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
December 27, 2021 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) in Each Cohort Satisfied the Bar...
November 29, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China

First Approval of a Subcutaneously Administered Checkpoint Inhibitor TRACON’s Pivotal U.S. Trial for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Continues to Advance as...
November 11, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
November 03, 2021 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
October 27, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...